The oncology market is saturated with new drugs that target the immune system, however, these only target part of the problem caused by cancer’s ability to hide from the immune system. Miguel Ferreira discusses why emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with…
List view / Grid view
Filter the results
T cell-based therapies have shown promise as new treatment options for various cancers.
Expert view: The path to the high-hanging fruit: access to greater diversity and rapid down-selection
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.